Modality
ERT
MOA
FcRni
Target
BCMA
Pathway
Neuroinflam
NMOSD
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
~Oct 2017
→ ~Jan 2019
Phase 3
~Apr 2019
→ ~Jul 2020
NDA/BLA
Oct 2020
→ Jun 2030
NDA/BLACurrent
NCT06741512
2,347 pts·NMOSD
2021-04→2030-06·Completed
NCT04689108
846 pts·NMOSD
2020-10→2026-01·Active
3,193 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-262mo agoPh3 Readout· NMOSD
2030-06-024.2y awayPh3 Readout· NMOSD
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Active
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-01-26 · 2mo ago
NMOSD
Ph3 Readout
2030-06-02 · 4.2y away
NMOSD
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06741512 | NDA/BLA | NMOSD | Completed | 2347 | Biomarker |
| NCT04689108 | NDA/BLA | NMOSD | Active | 846 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA |